Director, Oncology Translational Research
Scorpion Therapeutics, Cambridge, Massachusetts, us, 02140
Role Summary
This role is a key scientific leader and integral part of the Oncology Translational Research global leadership team, accountable for overseeing the generation and integration of genomic, transcriptomic, and proteomic data to deepen our understanding of cancer biology and guide the development of multiple therapeutic modalities. The role leads forward and reverse translational research for preclinical and clinical oncology programs, including exploratory clinical biomarker development of high-plex molecular assays, and interfaces with drug discovery, oncology data sciences, early clinical development, and late-stage development teams. Responsibilities
Directs successful translation of pre-clinical research to human clinical trials, leveraging learnings from genomic, transcriptomic, and proteomic analyses of preclinical models and patient samples. Guides exploratory biomarker plan design and strategy for early-stage Translational Clinical Oncology (TCO) and Global Drug Development (GDD) trials, serving as a core member of the Biomarker Review Committee. Integrates pre-clinical and emerging clinical efficacy and biomarker data to understand cancer biology and mechanisms of response and resistance to therapy in patients. Leverages quantitative/computational background to collaborate with Oncology Data Science to analyze high-dimensional preclinical and clinical data to guide clinical decisions and inform research strategy. Explores and onboards innovative technologies to advance translational research and new biomarker development. Responsible for quality and compliance of exploratory molecular biomarker assays. Interfaces with late-stage clinical development to enable translational research and development of regulated biomarker assays. Leads a team driving genomic, transcriptomic, and proteomic preclinical and clinical data creation, enabling AI/ML modeling and generating actionable insights. Develops talent by mentoring, coaching, and serving as an educational resource. Represent leadership at senior levels and in disease boards and other internal/external forums as a member of the Oncology Translational Research global leadership team. Qualifications
Required:
M.D., Ph.D., or comparable doctoral degree in a relevant discipline; on-site at Cambridge, MA with travel up to 10% (domestic and/or international); 6+ years of experience in pharma/biotech or academia in a matrixed leadership role. Outstanding scientific depth and breadth with a track record of high-impact publications in oncology and/or molecular pathology; strong leadership presence with ability to develop talent and influence others. Experience working with senior leaders and collaboration with junior associates; excellent analytical and communication skills; strong quantitative/computational background and broad knowledge in oncology with a track record of innovation. Preferred:
Demonstrated leadership in oncology/molecular pathology (typically >6 years); completion of a Molecular Genetic Pathology fellowship with board certification from the American Board of Pathology or American Board of Medical Genetics and Genomics.
#J-18808-Ljbffr
This role is a key scientific leader and integral part of the Oncology Translational Research global leadership team, accountable for overseeing the generation and integration of genomic, transcriptomic, and proteomic data to deepen our understanding of cancer biology and guide the development of multiple therapeutic modalities. The role leads forward and reverse translational research for preclinical and clinical oncology programs, including exploratory clinical biomarker development of high-plex molecular assays, and interfaces with drug discovery, oncology data sciences, early clinical development, and late-stage development teams. Responsibilities
Directs successful translation of pre-clinical research to human clinical trials, leveraging learnings from genomic, transcriptomic, and proteomic analyses of preclinical models and patient samples. Guides exploratory biomarker plan design and strategy for early-stage Translational Clinical Oncology (TCO) and Global Drug Development (GDD) trials, serving as a core member of the Biomarker Review Committee. Integrates pre-clinical and emerging clinical efficacy and biomarker data to understand cancer biology and mechanisms of response and resistance to therapy in patients. Leverages quantitative/computational background to collaborate with Oncology Data Science to analyze high-dimensional preclinical and clinical data to guide clinical decisions and inform research strategy. Explores and onboards innovative technologies to advance translational research and new biomarker development. Responsible for quality and compliance of exploratory molecular biomarker assays. Interfaces with late-stage clinical development to enable translational research and development of regulated biomarker assays. Leads a team driving genomic, transcriptomic, and proteomic preclinical and clinical data creation, enabling AI/ML modeling and generating actionable insights. Develops talent by mentoring, coaching, and serving as an educational resource. Represent leadership at senior levels and in disease boards and other internal/external forums as a member of the Oncology Translational Research global leadership team. Qualifications
Required:
M.D., Ph.D., or comparable doctoral degree in a relevant discipline; on-site at Cambridge, MA with travel up to 10% (domestic and/or international); 6+ years of experience in pharma/biotech or academia in a matrixed leadership role. Outstanding scientific depth and breadth with a track record of high-impact publications in oncology and/or molecular pathology; strong leadership presence with ability to develop talent and influence others. Experience working with senior leaders and collaboration with junior associates; excellent analytical and communication skills; strong quantitative/computational background and broad knowledge in oncology with a track record of innovation. Preferred:
Demonstrated leadership in oncology/molecular pathology (typically >6 years); completion of a Molecular Genetic Pathology fellowship with board certification from the American Board of Pathology or American Board of Medical Genetics and Genomics.
#J-18808-Ljbffr